Experimental studies in 1997 proved that hexarelin could reverse the cardiac dysfunction in GH-deficient animals immunized by the administration of an anti-GHRH serum. Ex vivo and in vivo systems converged to document that hexarelin progressively and globally improved LV function even under postischemic scenarios. These experiments showed that the synthetic secretagogue protective activity was independent from any further stimulation derived from the somatotropic function.26 In 1998, this group demonstrated that hexarelin protected against postischemic ventricular dysfunction in senescent hearts of aged male rats. Both ex vivo and in vivo, GHRPs offered a striking heart protection against reperfusion stunning, improved ventricular pressures and volumes, and reduced CK concentration in perfusate. Again, they sustained the concept that the protection afforded by the peptide is likely due to a direct cardiotropic action that appeared far greater than that induced by GH administration in a concurrent control group.27 A more defining protocol was assumed in 1999 as the study included hypophysectomized rats, to ascertain whether hexarelin had non-GH-mediated protective effects on the heart. The authors showed that hexarelin attenuated the ischemia/reperfusion damage and prevented elevation of LV end-diastolic pressure, coronary perfusion pressure, reactivity of the coronary vasculature to angiotensin II, and the release of creatine kinase in hypophysectomized animals.28 These three experiments were pivotal to define GHRP intrinsic cardioprotective ability.
Immunohistochemical determination of CD31 expression (platelet endothelial cell adhesion molecule-1, PECAM-1) was conducted as this is a marker protein of mature vascular endothelium [19]. Sections (5 μm) were mounted on chromalum-coated slides, dewaxed, rehydrated, rinsed, and washed in PBS 1x solution for 30 min. Once endogenous peroxidase was quenched, the specimens were treated with target retrieval solution (Dako) equilibrated at 99°C. Tissue samples were then incubated for 40 min with 1/50 dilution of anti-CD31 antibody (Abcam 28364, USA) in background reducing solution (Dako). The immunohistochemical reactions were carried out using the labelled streptavidin/biotin-horseradish peroxidase conjugate method, according to the manufacturer’s instructions (Dako). The peroxidase reaction was developed with diaminobenzidine and counterstained with hematoxylin.
The importance of limiting myocardial ischemia/reperfusion injury has been appreciated since Braunwald23,24 proposed that the extent and severity of tissue damage were not predetermined at the onset of ischemia, but could be modified by therapeutic manipulations applied during ischemia. Few years ago, a National Institutes of Health (NIH) expert’s panel concluded that cardioprotection is at a crossroads since approaches to identify cardioprotective therapies have been disappointing during the past 30 years.25 This may be related to the fact that the multiple candidates assayed so far target one single pathogenic event of the multiple damage cascade involved in myocardial damage and failure.25
GHRH/GHRP-6 was the first of a family of synthetic peptides that enhance the release of the GH by the pituitary gland in a dose-dependent manner. Since its discovery, it has been used as a benchmark and starting point for many of the research aims to obtain new drugs, but none of its implications are more engaging than the treating of the obesity epidemic.
The matters under subsection 52E (1) of the Therapeutic Goods Act 1989 considered relevant by the Committee included: a) the risks and benefits of the use of a substance; b) the purposes for which a substance is to be used and the extent of use of a substance; c) the toxicity of a substance; d) the dosage, formulation, labelling, packaging and presentation of a substance; and f) any other matters that the Secretary considers necessary to protect public health.
Various experiments have been conducted to test the effectiveness of CJC 1295-DAC in vivo and the Journal of Clinical Endocrinology & Metabolism has reported dose-dependent increases in mean plasma GH concentrations by 2-10 fold for more than 6 days and increased IGF-1 concentrations 1.5-3 fold for 9-11 days after a single injection. Mean half-life was shown to be 5.8-8.1 days, also after multiple doses mean IGF-1 levels remained above baseline for up to 28 days. No serious adverse reactions were reported in any group.

Growth Hormone Releasing Peptide 6 ( GHRP-6) is a peptide which substantially activates the pituitary gland into releasing high levels of growth hormone for a few hours. The increase in growth hormone comes from your own body, not synthetic growth hormones which can suppress your natural production. GHRP 6 is a first generation GHRP and has a few side effects which could be annoying.
Now these artificially manufactured compounds can replicate certain hormones within the human body to signal or trigger certain effects. Whereas GH (a total protein hormone of 191 amino acids), can attach to receptors at multiple sites within the body to influence different effects (say muscle cells, bone cells and fats cells, to name but three), shorter peptides have been isolated to trigger certain effects in a specific area/s. Imagine it’s like having a full tool box which you can mend a whole car with, but then you take certain tools out for different jobs and keep them apart in separate drawers which do specific jobs…sort of.
Despite their potent and reproducible GH-releasing activity, the clinical use of GHRPs as orally active growth-promoting agents and anabolic antiaging drugs remains to be confirmed.13 Accordingly, the early years’ enthusiasm as an alternative for GH replacement therapy faded away soon after their discovery.16 Nevertheless, it is likely that the myocardial, vascular, and multiorgan expression of the GHRP receptors may have contributed to reinforce the cardiovascular application stream of these peptides.
On the legality issue, peptides are always classed as ‘research chemicals’, not intended for human use. This is because anything that was intended for human use and especially compounds that are meant to be injected, would have to undergo intensive human research and testing, taking many years before approval. They are classed as research chemicals for use in lab experiments ONLY, which is why on the forums you will see guys talking about injecting their rat/rabbits/guinea pigs with peptides, etc., not specifically saying they are injecting themselves, as a get out clause if any legal repercussions came about.
Adults do not stop producing growth hormone as they get older; in fact, it's a myth that's spread by the HRT/TRT industry. However, as you get older, it's harder to activate the body’s release or pulse of growth hormone as frequently as you did when you were still growing; hence, the term “when I was younger...”. Who doesn't remember how great they felt at 18, versus 38!

High testosterone at this stage will accelerate the process. The SARMs are not testosterone, and don’t get metabolised into DHT (nor estradiol). The SARMs selectively bind to the androgen receptor in muscle and bone and amplify the effect of testosterone and DHT there, while not amplifying the effect on other tissue ie skin, prostate. However, through inheritance, if you have hair androgen receptors that are similar to muscle/bone androgen receptors, then SARMs can amplify the androgen message in the hair follicles, and if the inherited androgen sensitivity is activated, it could lead to accelerated male pattern baldness. This is a very rare variation, and while possible, is uncommon. There are no tests available to determine SARMs effect on your hair follicles, nor to determine when your genetic androgen sensitivity in hair follicles will activate.
People who have taken in GHRP 6 supplements have reported to have experienced improved joint health, perfect night’s rest and a sense of being fine throughout the day. Therefore, in a way, supplements that are based on GHRP 6 are considered ideal and can be used under physician’s guidance. The dosage required for an individual will largely depend on his or her requirements. For example, if your only aim is to improve the health of your joints and sleep aid, then consider having a small dose. However, if you are a professional bodybuilder you may need to up your dosage considerably. Only by this way you will be able to gain extra muscle mass in a record quick time. However, patience is the key whenever you are using supplements that are based on GHRP 6 and GHRP 2. For bodybuilders, athletes and other professionals, the desired results can be seen quickly only when they are self-motivated. GHRP 6 and GHRP 2-based supplements can only help them in the process.
MuscleSport PCT Revolution ADVANCED POST-CYCLE THERAPY PCT Revolution should be used after the use of any SARM. This ensures natural testosterone production increases and excess estrogen production is reduced. When your body produces abnormally high levels of testosterone for an extensive period of time you need to get your system back firing on all cylinders. Post-Cycle Therapy does just that.…
This article or section may have been copied and pasted from another location, possibly in violation of Wikipedia's copyright policy. Please review the source and remedy this by editing this article to remove any non-free copyrighted content and attributing free content correctly, or flagging the content for deletion. Please be sure that the supposed source of the copyright violation is not itself a Wikipedia mirror. (December 2016)
×